Melevodopa

Melevodopa
Clinical data
Trade names	Levomet
Other names	Levodopa methyl ester; L-DOPA methyl ester; LDME; CHF-1301
ATC code	N04BA04 (WHO) ;
Identifiers
	IUPAC name methyl (2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoate;
CAS Number	7101-51-1;
PubChem CID	23497;
ChemSpider	21968 ;
UNII	M30686U4X4;
KEGG	D07304 ;
CompTox Dashboard (EPA)	DTXSID9048433 ;
Chemical and physical data
Formula	C10H13NO4
Molar mass	211.217 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C(OC)[C@@H](N)Cc1cc(O)c(O)cc1;
	InChI InChI=1S/C10H13NO4/c1-15-10(14)7(11)4-6-2-3-8(12)9(13)5-6/h2-3,5,7,12-13H,4,11H2,1H3/t7-/m0/s1 ; Key:XBBDACCLCFWBSI-ZETCQYMHSA-N ;
	(verify)

Melevodopa, also known as levodopa methyl ester (LDME) and sold under the brand name Levomet, is a dopaminergic agent. It is the methyl ester of levodopa.^[1] It is used in oral tablet form as an effervescent prodrug with 250 times the water solubility of tablet levodopa.^[2]^[3] In combination with carbidopa, as melevodopa/carbidopa (brand name Sirio), it is approved for use in the treatment of Parkinson's disease.^[4]^[5]

References

^ Buckingham J, Baggaley K, Roberts A, Szabo L (2010). Dictionary of Alkaloids with CD-ROM. CRC Press. p. 103. ISBN 978-1-4200-7770-4. Retrieved 28 September 2024.
^ Hickey P, Stacy M (2011). "Available and emerging treatments for Parkinson's disease: a review". Drug Design, Development and Therapy. 5: 241–254. doi:10.2147/DDDT.S11836. PMC 3096539. PMID 21607020.
^ Stocchi F, Marconi S (July 2010). "Factors associated with motor fluctuations and dyskinesia in Parkinson Disease: potential role of a new melevodopa plus carbidopa formulation (Sirio)". Clin Neuropharmacol. 33 (4): 198–203. doi:10.1097/WNF.0b013e3181de8924. PMID 20414107.
^ "Melevodopa/carbidopa". AdisInsight. Springer Nature Switzerland AG. 23 September 2021. Retrieved 27 September 2024.
^ "Melevodopa: Uses, Interactions, Mechanism of Action". DrugBank Online. 1 April 2015. Retrieved 27 September 2024.